Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.61 |
| ▸ | CPB1 | P15086 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5493238 | 1.00 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| Hydrochloric Acid SCHEMBL4329921 | 0.98 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| Hydrochloric Acid SCHEMBL5279548 | 0.98 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| Hydrochloric Acid SCHEMBL6375520 | 0.98 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL335088 | 0.98 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL4363476 | 0.97 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL7863455 | 0.97 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL235394 | 0.97 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL3049211 | 0.97 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL19240717 | 0.97 | HTT (0.68) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534429-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| WO-2025202493-A1 | ANTIMICROBIAL PEPTOID TERPOLYMERS, PREPARATIONS AND USES THEREOF | VIKYNG AI (FR) | 2025-10-02 | — | — | WO | disclosed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025067317-A1 | LIPID-MODIFIED NUCLEIC ACID COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 上海拓界生物医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-11859018-B2 | Peptoid-based chelating ligands for selective metal chelation | TRIAD NATIONAL SECURITY, LLC (US) | 2024-01-02 | — | — | US | disclosed |
| CN-107973809-B | Macrocyclic compounds as factor XIA inhibitors | 百时美施贵宝公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-115996755-A | Bifunctional molecules and methods of use thereof | 旗舰创业创新VI有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115916262-A | Bifunctional molecules and methods of use thereof | 旗舰创业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115916219-A | Bifunctional molecules and methods of use thereof | 旗舰创业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20230095637-A1 | Heterodimers of Glutamic Acid | CITIZENS BANK, N.A. | 2023-03-30 | — | — | US | disclosed |
| US-7375087-B2 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-20 | — | — | US | disclosed |
| EP-1778652-A2 | COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS | EntreMed, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060166899-A1 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20060063930-A1 | Compositions and methods comprising proteinase activated receptor antagonists | ENTREMED, INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006023844-A2 | COMPOSITIONS AND METHODS COMPRISING PROTEINASE ACTIVATED RECEPTOR ANTAGONISTS | ENTREMED, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1544208-A1 | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-06-22 | — | — | EP | disclosed |
| CN-1308608-A | Substituted beta-amino acid inhibitors of methionine aminopeptidase-2 | ABBOTT LAB (US) | 2001-08-15 | — | — | CN | disclosed |
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | disclosed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166899-A1 | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | SLC5A1, SLC5A2, SULT2A1 | HTT 1753/4885TGM2 1291/4885LMNA 4724/4885 |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | HTT 2077/4885TGM2 2170/4885LMNA 1757/4885 |
| US-12534429-B2 | Heterodimers of glutamic acid | FOLH1, GLUL, SLC25A13 | HTT 4543/4885TGM2 44/4885LMNA 4266/4885 |
| US-20060063930-A1 | Compositions and methods comprising proteinase activated receptor antagonists | F2RL1, PLAUR, F2R | HTT 3539/4885TGM2 1900/4885LMNA 3260/4885 |
| US-20230095637-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | HTT 4210/4885TGM2 111/4885LMNA 4551/4885 |
| US-11859018-B2 | Peptoid-based chelating ligands for selective metal chelation | SLC39A14, SLC39A11, SLC40A1 | HTT 985/4885TGM2 328/4885LMNA 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.